Atypical retinal pigment epithelial defects with retained photoreceptor layers: a so far disregarded finding in age related macular degeneration

Table 1 Clinical presentation and ocular characteristics of included patients

#	Eye	Lesion prior to RPE defect	F/u (mo)	BL BCVA	Final BCVA	Treatment after RPE defect	SRF duration (month)	OCT-A	HypoFAF area F/u	Mi-gration	RPE defect (OCT)	Presentation Fellow eye
1	OD	drusenoid PED	36	20/20	20/20	3× bevacizumab	12	-	↓	+	↓	Drusen, RPD
2	OS	N.A.	60	20/160	20/200	none	0	-	↓	+	↓	Occult CNV
3	OS	N.A.	120	20/50	20/200	2× retaane, 37× ranibizumab	persistent	No NV network	↑	-	↑	Drusenoid PED, IRC, atrophy
4	OD	drusenoid PED	60	20/40	20/125	32× ranibizumab	persistent	No NV network	↑	-	↑	Drusenoid PED, RPD
5	OD	drusenoid PED	12	20/25	20/25	2× ranibizumab	7	-	↓	+	↓	Drusen
6	OS	drusenoid PED	36	20/40	20/63	none	persistent	-	↑	-	↑	St.p. macular hole, Drusen
7	OS	Drusen	6	20/70^a	20/30	none	0	No NV network	↓	+	↔	Fibrovascular scar, Drusen

Clinical characteristics of the 7 included patients all diagnosed with AMD and presenting with a center-involving RPE defect with intact overlying photoreceptor layers and a minimum of follow up of 6 months. All included cases were treatment naïve without evidence of a choroidal neovascularization when diagnosed
RPE retinal pigment epithelium, BCVA best corrected visual acuity, SRF subretinal fluid, BL Baseline, F/u duration of follow up between initial presentation of RPE-defect and last visit, FAF fundus autofluorescence, IRC intraretinal cysts, NV neovascular, Migration migration of subretinal drusenoid/RPE material
^ainitial BCVA was performed prior to cataract surgery

ISSN: 1471-2415